![Benjamin Scruggs](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Benjamin Scruggs
Directeur Général chez
Altis Biosystems, Inc.
Profil
Benjamin Scruggs currently works at Altis Biosystems, Inc., as Chief Executive Officer & Director, Veralox Therapeutics, Inc., as Director from 2021, IMMvention Therapeutix, Inc., as Director, Tune Therapeutics, Inc., as Senior Director from 2022, and Hatteras Venture Partners, as Partner from 2025.
Dr. Scruggs received his doctorate degree in 2012 from Washington University in St. Louis and undergraduate degree in 2006 from Vanderbilt University.
Postes actifs de Benjamin Scruggs
| Sociétés | Poste | Début |
|---|---|---|
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Private Equity Investor | 01/01/2021 |
IMMvention Therapeutix, Inc.
 IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Directeur/Membre du Conseil | - |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Directeur/Membre du Conseil | 01/06/2021 |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. BiotechnologyHealth Technology Operates epigenome treatment medicines | Directeur/Membre du Conseil | 01/01/2022 |
Altis Biosystems, Inc.
 Altis Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Develops stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research | Directeur Général | 01/02/2023 |
Formation de Benjamin Scruggs
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
94
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Finance |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Health Technology |
Altis Biosystems, Inc.
Altis Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Develops stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research | Health Technology |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Health Technology |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. BiotechnologyHealth Technology Operates epigenome treatment medicines | Health Technology |
